Comparison between metformin and glibenclamide as antidiabetic oral in gestational diabetes mellitus: a review

Firda Ridhayani; I Dewa Agung Ayu Diva Candraningrat; Ilmi Nurhafizah; Karina Nurlitasari; Mardiana Siregar

doi:10.22146/ijpther.5867

Firda Ridhayani
I Dewa Agung Ayu Diva Candraningrat Master of Clinical Pharmacy, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta
Ilmi Nurhafizah Master of Clinical Pharmacy, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta
Karina Nurlitasari Master of Clinical Pharmacy, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta
Mardiana Siregar Master of Clinical Pharmacy, Faculty of Pharmacy, Universitas Gadjah Mada, Yogyakarta

DOI: https://doi.org/10.22146/ijpther.5867

Keywords: metformin, glyburide, glibenclamide, gestational, diabetes

Abstract

Gestational diabetes mellitus (GDM) is one of the most frequent clinical complications during pregnancy that affects up to 6% of women with pregnancies around the world. Gestational diabetes mellitus treatment used insulin as first-line therapy. In addition, several professional associations are also considering treatment using antidiabetic oral which has equivalent efficacy compared with insulin. However, many oral antidiabetic recommendations have been administered to treat GDM, including metformin and glyburide or glibenclamide. This article’s review aims to compare the usage between metformin and glyburide or glibenclamide in GDM patients. This review compared research results from PubMed as literature resources and the PRISMA flow chart as the protocol for the article selection process. Based on inclusion and exclusion criteria there are six research articles that are appropriate to the article’s topic and aim. Metformin is superior compared with glyburide or glibenclamide administration as antidiabetic oral in GDM. Metformin showed a significant effect in lowering preprandial and postprandial glucose level, elevating insulin sensitivity, while glibenclamide administration decreased dynamic pancreatic β-cell responsivity significantly and had a higher risk compared with insulin and metformin.

References

1. Mack, L.R. and Tomich, P.G., 2017. Gestational diabetes: diagnosis, classification, and clinical care. Obstetrics and Gynecology Clinics, 44(2), pp.207-217.
2. Langer, O., Conway, D.L., Berkus, M.D., Xenakis, E.M.J. and Gonzales, O., 2000. A comparison of glyburide and insulin in women with gestational diabetes mellitus. New England Journal of Medicine, 343(16), pp.1134-1138.
3. Coetzee EJ. Pregnancy and diabetes scenario around the world: Africa. Int J Gynaecol Obstet 2009;104:S39-41.
4. Lain KY, Garabedian MJ, Daftary A, Jeyabalan A. Neonatal adiposity following maternal treatment of gestational diabetes with glyburide compared with insulin. Am J Obstet Gynecol 2009;200:501.e501-506.
5. Rowan JA, Hague WM, Gao W, Battin MR, Moore MP. Metformin versus insulin for the treatment of gestational diabetes. N Engl J Med 2008;358:2003-15.
6. Silva JC, Fachin DR, Coral ML, Bertini AM. Perinatal impact of the use of metformin and glyburide for the treatment of gestational diabetes mellitus. J Perinat Med 2012;40:225-8.
7. Jacobson GF, Ramos GA, Ching JY, Kirby RS, Ferrara A, Field DR. Comparison of glyburide and insulin for the management of gestational diabetes in a large managed care organization. Am J Obstet Gynecol 2005;193:118-24.
8. Balsells, M., García-Patterson, A., Solà, I., Roqué, M., Gich, I. and Corcoy, R., 2015. Glibenclamide, metformin, and insulin for the treatment of gestational diabetes: a systematic review and meta-analysis. Bmj, 350.
9. Metzger BE, Buchanan TA, Coustan DR, de Leiva A, Dunger DB, Hadden DR, et al.Summary and recommendations of the Fifth International Workshop-Conference on Gestational Diabetes Mellitus. Diabetes Care 2007;30(suppl 2):S251-60.
10. Camelo Castillo W, Boggess K, Sturmer T, Brookhart MA, Benjamin DK Jr, Jonsson Funk M. Trends in glyburide compared with insulin use for gestational diabetes treatment in the United States, 2000-2011. Obstet Gynecol 2014;123:1177-84.
11. National Institute for Health and Care Excellence. Diabetes in pregnancy: management of diabetes and its complications from pre-conception to the postnatal period. (Clinical guideline 63.) 2008. www.nice.org.uk/guidance/cg63/.
12. Committee on Practice Bulletins—Obstetrics. Practice bulletin No. 137: gestational diabetes mellitus. Obstet Gynecol 2013;122:406-16.
13. Nachum Z, Zafran N, Salim R, Hissin N, Hasanein J, Gam Ze Letova Y, et al. Glyburide versus metformin and their combination for the treatment of gestational diabetes mellitus: a randomized controlled study. Diabetes Care 2017;40:332–7.
14. Reynolds RM, Denison FC, Juszczak E, Bell JL, Penneycard J, Strachan MWJ, et al. Glibenclamide and metfoRmin versus stAndard care in gEstational diabeteS (GRACES): a feasibility open label randomised trial. BMC Pregnancy Childbirth 2017;17:316.
15. Shuster, D. L., Shireman, L. M., Ma, X., Shen, D. D., Flood Nichols, S. K., Ahmed, M. S., ... & Hebert, M. F. (2020). Pharmacodynamics of glyburide, metformin, and glyburide/metformin combination therapy in the treatment of gestational diabetes mellitus. Clinical Pharmacology & Therapeutics, 107(6), 1362-1372.
16. Guo, L., Ma, J., Tang, J., Hu, D., Zhang, W., & Zhao, X. (2019). Comparative efficacy and safety of metformin, glyburide, and insulin in treating gestational diabetes mellitus: a meta-analysis. Journal of diabetes research, 2019.
17. Liao, M.Z., Flood Nichols, S.K., Ahmed, M., Clark, S., Hankins, G.D., Caritis, S., dkk., 2020. Effects of Pregnancy on the Pharmacokinetics of Metformin. Drug Metabolism and Disposition, 48: 264–271.
18. George, A., Mathews, J.E., Sam, D., Beck, M., Benjamin, S.J., Abraham, A., dkk., 2015. Comparison of neonatal outcomes in women with gestational diabetes with moderate hyperglycaemia on metformin or glibenclamide - A randomised controlled trial. Australian and New Zealand Journal of Obstetrics and Gynaecology, 55: 47–52.
19. American Diabetes Association Professional Practice Committee; 15. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes—2022. Diabetes Care 1 January 2022; 45 (Supplement_1): S232–S243.
20. American Diabetes Association. 13. Management of Diabetes in Pregnancy: Standards of Medical Care in Diabetes—2018. Diabetes Care 2018;41:S137–43
21. Society of Maternal-Fetal (SMFM) Publications Committee. Electronic address: pubs@smfm.org. SMFM Statement: Pharmacological treatment of gestational diabetes SMFM Publications Committee. Am J Obstet Gynecol; 2018.
22. NICE. Diabetes in pregnancy. Management of diabetes and its complications from preconception to the postnatal period; 2015.
23. Thompson D, Berger H, Feig D, Gagnon R, Kader T, Keely E, et al. Diabetes and pregnancy. Can J Diab 2013;37:S168–83.
24. Blumer I, Hadar E, Hadden DR, Jovanovicˇ L, Mestman JH, Murad MH, et al. Diabetes and pregnancy: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2013;98:4227–49.